Safety and Efficacy Study of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI as Second Line Therapy in Participants With KRAS Wild-Type Metastatic Colorectal Cancer (mCRC)
Public ClinicalTrials.gov record NCT01652482. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Multicenter, Open-Label, Randomized Study Evaluating the Efficacy and Safety of MEHD7945A + FOLFIRI Versus Cetuximab + FOLFIRI in Second Line in Patients With KRAS Wildtype Metastatic Colorectal Cancer
Study identification
- NCT ID
- NCT01652482
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Genentech, Inc.
- Industry
- Enrollment
- 135 participants
Conditions and interventions
Conditions
Interventions
- 5-fluorouracil Drug
- Cetuximab Drug
- Irinotecan Drug
- Leucovorin Drug
- MEHD7945A Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2012
- Primary completion
- Oct 31, 2014
- Completion
- Oct 31, 2014
- Last update posted
- Nov 1, 2016
2012 – 2014
United States locations
- U.S. sites
- 19
- U.S. states
- 12
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Bakersfield | California | 93309 | — |
| Not listed | Fullerton | California | 92835 | — |
| Not listed | Los Angeles | California | 90033 | — |
| Not listed | Los Angeles | California | 90095 | — |
| Not listed | San Luis Obispo | California | 93454 | — |
| Not listed | Santa Barbara | California | 93105 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | Orange Park | Florida | 32073 | — |
| Not listed | Harvey | Illinois | 60426 | — |
| Not listed | Paducah | Kentucky | 42003 | — |
| Not listed | Rockville | Maryland | 20850 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Boston | Massachusetts | 02215 | — |
| Not listed | Detroit | Michigan | 48201 | — |
| Not listed | Jefferson City | Missouri | 65109 | — |
| Not listed | Las Vegas | Nevada | 89148 | — |
| Not listed | Philadelphia | Pennsylvania | 19104 | — |
| Not listed | Kirkland | Washington | 98034 | — |
| Not listed | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01652482, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 1, 2016 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01652482 live on ClinicalTrials.gov.